ClinicalTrials.gg
RecruitingNCT07875829Updated Oct 15, 2026

Quality of Recovery After Colorectal Surgery (Robots vs Laparoscopic)

An interventional study of Robotic vs laparoscopic surgery in Recovery Outcomes, sponsored by Hospital Central do Funchal. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Hospital Central do Funchal · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2026, registered Oct 2026).
  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 15, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Minimally invasive techniques for colorectal surgery include standard laparoscopy and robot-assisted laparoscopy. Studies evaluating recovery after anaesthesia and surgery have focused primarily on physiological endpoints, recovery times, and the incidence of adverse events, such as major morbidity and mortality. Although these parameters are essential and should be measured, they mostly ignore the patient's perspective. Patient-related outcomes can be assessed with tools designed for that purpose, such as the Quality of Recovery-15 (QoR-15) questionnaire.

This single-centre prospective observational cohort study will compare robotic vs laparoscopic colorectal resections with the primary outcome of QoR-15 at 24 hours after surgery, capturing anaesthesia-specific variables to adjust for confounding.

Read the detailed description
  1. Background and rationale Minimally invasive techniques for colorectal surgery include standard laparoscopy and robot-assisted laparoscopy. Studies evaluating recovery after anaesthesia and surgery have focused primarily on physiological endpoints, recovery times, and the incidence of adverse events, such as major morbidity and mortality. Although these parameters are essential and should be measured, they mostly ignore the patient's perspective. Patient-related outcomes can be assessed with tools designed for that purpose, such as the Quality of Recovery-15 (QoR-15) questionnaire.

    This single-centre prospective observational cohort study will compare robotic vs laparoscopic colorectal resections with the primary outcome of QoR-15 at 24 hours after surgery, capturing anaesthesia-specific variables to adjust for confounding.

  2. Objectives Primary objective: To compare patient-reported quality of recovery (QoR-15 total score) at 24 hours postoperatively between patients undergoing surgeon-allocated robotic vs laparoscopic colorectal surgery following ERAS protocol.

    Secondary objectives:

    • Compare QoR-15 at PACU discharge and at 48h.
    • Compare pain scores, opioid consumption (first 24 and 48 h), PONV rates, PACU time, intraoperative hemodynamic instability events, length of hospital stay, complications (Clavien-Dindo), and 30-day readmission.
  3. Study design Prospective, single-centre, observational cohort study. Allocation to robotic vs laparoscopic is determined by the operating surgeon (non-randomised). The anaesthetist will enrol and collect preop, intraop and postop data. Statistical methods will adjust for confounding (propensity-score methods, multivariable regression, clustering by surgeon).
  4. Inclusion / exclusion criteria Inclusion: Age ≥ 18 years, scheduled for elective colorectal resection (laparoscopic or robot-assisted), ASA I-III, able to consent and complete QoR-15, included in ERAS pathway.

    Exclusion: Emergency surgery, concomitant major non-colorectal procedure, severe cognitive impairment, refusal/inability to consent.

  5. Outcomes and definitions Primary outcome: QoR-15 total score (0-150) at 24 hours after surgery (±4 h window). Secondary outcomes: QoR-15 at PACU, 48/72 h; pain scores; opioid use; PONV; PACU and OR times; intraop hemodynamics; LOS; complications; 30-day readmission.
  6. Anaesthesia recommendations and recording Standardized induction (propofol, fentanyl, rocuronium), maintenance (TIVA), multimodal analgesia, and antiemetic prophylaxis. All drugs, doses, fluid management, temperature, and monitoring to be recorded.
  7. Data collection (CRF) Detailed CRF variable list includes baseline demographics, comorbidities, preop QoR-15, surgical and anaesthetic details, intraop events, PACU data, postoperative QoR-15, pain, PONV, complications, and LOS. Use validated QoR-15 translation, time-stamp each administration.
  8. Sample size and power According to the previous literature, the standard deviation (SD) of the total QoR-15 score in the Portuguese population is 14 [7]. An 8-point difference in the QoR-15 score represents the MCID that defines if the quality of recovery was improved (a positive 8-point difference) or worsened (a negative 8-point difference) [8, 9]. A minimum of 49 patients in each group were obtained (3 = 0.05 and 4 = 0.20). Considering 10% possible losses during the study (dropouts), the final sample constituted 110 patients.

    Parameters: alpha=0.05, 80% power, MCID 6-10 points, SD 12-22. Formula: n per group = 2 × (Zα/2 + Zβ)\^2 × σ\^2 / δ\^2. Example: For MCID=8, SD=14 → \~49 per group (98 total). Considering \~ 10% added for missing data, final sample is 110 (55 per group). Sample size table attached in appendix.

  9. Statistical analysis plan Primary: Compare QoR-15 at 24 h using propensity-score matched analysis (linear mixed model adjusting for surgeon). Secondary: IPTW and regression with baseline covariates. Other outcomes analysed with appropriate models (logistic, Cox, etc.). Missing data handled with complete-case or multiple imputation. Sensitivity analyses include subgroups and alternative propensity approaches.
  10. Bias reduction and limitations Collect rich baseline/intraop data; adjust for surgeon clustering; standardize anaesthesia if possible. Limitations: residual confounding, single-centre generalisability.
  11. Operational considerations Pilot in first 20-30 patients to confirm SD and feasibility; train staff in CRF and QoR-15 administration; secure de-identified data storage.
  12. Ethical considerations Ethics approval required. Informed consent from all participants. Privacy and compliance complaint with data governance.
  13. Appendices QoR-15 questionnaire, Case Report Form (CRF), sample size table, Information leaflet, informed consent form attached.
02

Conditions studied

  • Recovery Outcomes
03

In context

Lead sponsor

Hospital Central do Funchal is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Age ≥ 18 years;
  • Elective colorectal resection (laparoscopic or robot-assisted);
  • ;
  • Ability to consent and complete QoR-15;
  • Inclusion in ERAS pathway.

Exclusion Criteria:

  • Emergency surgery;
  • Concomitant major non-colorectal procedure;
  • Severe cognitive impairment;
  • Refusal/inability to consent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Other
    Prospective, single-centre, observational cohort study. Allocation to robotic vs laparoscopic is det

    Procedure: Robotic vs laparoscopic surgery

Interventions

  • ProcedureRobotic vs laparoscopic surgery

    Prospective, single-centre, observational cohort study. Allocation to robotic vs laparoscopic is determined by the operating surgeon (non-randomised). The anaesthetist will enrol and collect preop, intraop and postop data. Statistical methods will adjust for confounding (propensity-score methods, multivariable regression, clustering by surgeon).

06

What researchers measure

Primary outcomes

  1. Primary outcome: Quality of Recovery-15 (QoR-15) total score at 24 hours after surgery (±4 h window).

    The total score ranges from 0 (very poor recovery) to 150 (excellent quality of recovery).

    Time frame: January 2026 - May 2027

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for May 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 15, 2026
StartActual
Jan 12, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Jul 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07875829
Lead sponsor
Hospital Central do Funchal
Responsible party
Ana Isabel Pereira (Assistente hospitalar, Hospital Central do Funchal) — Principal investigator
First posted
Oct 15, 2026
Start date
Jan 12, 2026
Primary completion
May 31, 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Ana I Pereira
Contact
2502anaisabel@gmail.com
+351 910 832 157

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion